BurnA
Senior Member
- Messages
- 2,087
That said, I think Kogelnik's actions of providing the drug outside of a trial is irresponsible. I think at the very least an open-label, trial with defined outcomes was warranted.
There is a big difference - the cost and risks of Rituximab are far higher. Surely some transparent data collection (ongoing open label trial) is not too much to ask?
This is somewhat a separate discussion but I'd like to add my opinion here.
IMO a doctor is responsible for taking care of their patients first and foremost. To prescribe a drug off label to a very sick patient carries a lot of responsibility. I don't see how this can be described as irresponsible at all. They are using their education and experience to make a massive, potentially life altering decision for a patient. That's what doctors do.
While we might all like to see more information on the use of RTX on patients, we are not entitled to this. And the cost of the drug is not a factor in this - why would it be ok to prescribe a cheap drug off label but not an expensive one? That would be irresponsible.
Don't get me wrong - I would love to see OMI publish all their data and perform registered trials but this is for my selfish reasons and for the broader good. But they don't have to do this. Whether they publicly documented all their work or not - it wouldn't change the outcome or cost for their individual patients, to whom their responsibility lies first and foremost.
Labelling them irresponsible is a step too far IMO.